ArticleBlood advances2019
Distinct clinical and biological implications of
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 45 citations in OpenAlex.
- Prognostic significance of CUX1 genomic deletion in myelodysplastic neoplasms.Annals of hematology · 2026Article
- Ancestry-dependent patterns of somatic mosaicism and clonal hematopoiesis mutations in over 125,000 individuals reveal distinct cancer associations.Human genomics · 2025Article
- Progress in the Genetics of Myelodysplastic Syndromes with a Latin American Perspective.Genes · 2025Review
- Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.Blood cancer journal · 2024Article
- CUX1 attenuates the apoptosis of renal tubular epithelial cells induced by contrast media through activating the PI3K/AKT signaling pathway.BMC nephrology · 2024Article
- 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.Leukemia · 2024Article
- Review
- RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives.Blood cancer journal · 2024Review
- Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.Current oncology (Toronto, Ont.) · 2024Review
- RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.Annals of medicine · 2023Article
- Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.Leukemia · 2023Article
- Article
- Next-Generation Sequencing-Based Genomic Profiling of Children with Acute Myeloid Leukemia.The Journal of molecular diagnostics : JMD · 2023Article
- Article
- Predicting leukemic transformation in myelodysplastic syndrome using a transcriptomic signature.Frontiers in genetics · 2023Article
- Article
- Genetic Background of Polycythemia Vera.Genes · 2022Review
- A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid Neoplasms.Cancer research communications · 2022Article
- Genomic studies controvert the existence of the CUX1 p75 isoform.Scientific reports · 2022Article
- Identification of differentially expressed autophagy genes associated with osteogenic differentiation in human bone marrow mesenchymal stem cells.American journal of translational research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 5 countries.
Mai AlyDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Zubaidah M RamdzanRosalind and Morris Goodman Cancer Research Centre, Department of Oncology, Biochemistry and Medicine, McGill University, Montreal, QC, Canada.
Yasunobu NagataDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Suresh K BalasubramanianDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Naoko HosonoDepartment of Hematology and Oncology, Faculty of Medical Science, University of Fukui, Fukui, Japan.
Hideki MakishimaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; and.
Valeria VisconteDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Teodora KuzmanovicDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Vera AdemaDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Aziz NazhaLeukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and.
Bartlomiej P PrzychodzenDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Cassandra M KerrDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Mikkael A SekeresLeukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, and.
Mohamed E AbazeedDepartment of Radiation Oncology, Cleveland Clinic, Cleveland, OH.
Alain NepveuRosalind and Morris Goodman Cancer Research Centre, Department of Oncology, Biochemistry and Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0002-6125-0850
Jaroslaw P MaciejewskiDepartment of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH.
Cleveland Clinic · USCancer Institute (WIA) · INMcGill University Health Centre · CAKyoto University · JPUniversity of Fukui · JP
Funding
TRANSLATIONAL RESEARCH ONCOLOGY TRAINING GRANTK12CA076917 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI GERSON, STANTON L. · 1997 to 2022
$14.2MInstitutional Career Development CoreKL2TR002547 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI DWEIK, RAED A. · 2018 to 2022
$7.7MTherapeutic Implications of Molecular Defects in Bone Marrow FailureR35HL135795 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P. · 2017 to 2023
$5.7MA biomarker-driven strategy to guide the use of radiotherapy in non-small cell lung cancerR37CA222294 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABAZEED, MOHAMED E. · 2018 to 2024
$2.5MNovel Spliceosomal Defects in Myelodysplastic SyndromesR01HL132071 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2016 to 2019
$2.4MRNA Helicase Mutations in Myelodysplastic Syndrome: New Therapeutic TargetR01HL123904 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI JANKOWSKY, ECKHARD, MACIEJEWSKI, JAROSLAW P. · 2015 to 2018
$2.1MInvestigations of Consequences of U2AF1 Mutations in MDSR01HL118281 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI MACIEJEWSKI, JAROSLAW P., PADGETT, RICHARD A · 2013 to 2017
$1.9MNCATS NIH HHS KL2 TR002547NCI NIH HHS K12 CA076917NCI NIH HHS R37 CA222294NHLBI NIH HHS R01 HL118281NHLBI NIH HHS R01 HL123904NHLBI NIH HHS R01 HL132071NHLBI NIH HHS R35 HL135795
Abstract
Somatic mutations of the CUT-like homeobox 1 (
Indexed as
Disease SusceptibilityBiomarkersChromosome AberrationsClonal EvolutionFemaleGene Expression ProfilingGenetic Association StudiesGenetic Predisposition to DiseaseHomeodomain ProteinsHumansKaplan-Meier EstimateLeukocytes, MononuclearLoss of HeterozygosityMaleMutationMyeloproliferative DisordersBiomarkersCUX1 protein, humanHomeodomain ProteinsRepressor ProteinsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.